Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma.
about
Oncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesCrizotinib synergizes with cisplatin in preclinical models of ovarian cancer.Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents.Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from Kras-driven lung tumours.
P2860
Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Synergistic Effects of Crizoti ...... Fusion-Positive Glioblastoma.
@ast
Synergistic Effects of Crizoti ...... Fusion-Positive Glioblastoma.
@en
type
label
Synergistic Effects of Crizoti ...... Fusion-Positive Glioblastoma.
@ast
Synergistic Effects of Crizoti ...... Fusion-Positive Glioblastoma.
@en
prefLabel
Synergistic Effects of Crizoti ...... Fusion-Positive Glioblastoma.
@ast
Synergistic Effects of Crizoti ...... Fusion-Positive Glioblastoma.
@en
P2093
P2860
P356
P1476
Synergistic Effects of Crizoti ...... Fusion-Positive Glioblastoma.
@en
P2093
Abhay K Varma
Arabinda Das
David Cachia
Megan L T Hilbert
Michele Decandio
Naren L Banik
Pierre Giglio
Ron Ron Cheng
Scott M Lindhorst
Sunil J Patel
P2860
P356
10.4137/CGM.S32801
P577
2015-12-01T00:00:00Z